|
Treatment (mg/kg)
|
Protein (μg/mg Tissue)
|
H2O2 (nM/min/mg Tissue)
|
Nitrite (content μM/ml)
|
TBARS (nM/min/mg protein)
|
|---|
|
Control
|
4.657 ± 0.047b
|
1.969 ± 0.056b
|
34.77 ± 1.323b
|
3.499 ± 0.156b
|
|
DOX
|
1.150 ± 0.049a
|
5.356 ± 0.074a
|
90.65 ± 1.787a
|
9.492 ± 0.427a
|
|
AHE alone
|
4.677 ± 0.149b
|
1.321 ± 0.057b
|
36.24 ± 0.958b
|
3.153 ± 0.087b
|
|
DOX + AHE (200)
|
3.200 ± 0.232a, b, d*
|
4.039 ± 0.021a, b, d
|
60.72 ± 2.577a, b, d
|
6.240 ± 0.589a, b
|
|
DOX + AHE (400)
|
4.128 ± 0.195b, c**
|
2.319 ± 0.038a**, b, c
|
43.25 ± 0.485a*, b, c
|
4.446 ± 0.217b, c*
|
|
DOX + Sily
|
3.985 ± 0.074b
|
2.336 ± 0.062a**, b
|
41.32 ± 1.194b
|
4.829 ± 0.067b
|
- Values expressed as mean ± SEM. a Significance at p < 0.0001 Vs. control group, b Significance at p < 0.0001 Vs. Doxorubicin (DOX) group, c Significance at p < 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d Significance at p < 0.0001 of AHE co-treatment groups Vs DOX + Sily group. *, ** Significant difference at p < 0.05 and p < 0.001 respectively. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin
